Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast CancerCook-Bruns N.
Pharmaceuticals Development Group, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Approximately 25,000 patients have been treated to date with the humanized anti-HER2 monoclonal antibody, Herceptin®. This therapy has proved effective and well tolerated in patients with HER2-positive metastatic breast cancer; adverse events were generally infusion-related fever and chills of mild-to-moderate severity. Cardiotoxicity and infusion-related reactions emerged as the two main safety concerns with the use of Herceptin. Retrospective analysis revealed a higher incidence of heart failure when Herceptin was combined with anthracyclines than that expected with anthracyclines alone. Age, anthracycline exposure and cardiac risk factors were found to be predictors of cardiac adverse events. Patients experiencing cardiac dysfunction responded well to standard cardiac medication and the majority improved. Cardiac function should be monitored regularly and Herceptin should be discontinued if significant heart failure develops unless the benefits for an individual patient outweigh the risks. Of 25,000 patients, 74 (0.3%) were reported to have experienced a serious infusion-related reaction. The majority occurred during or shortly after the first infusion and were characterized by respiratory symptoms. Most patients were successfully treated; a total of 33 patients continued Herceptin therapy with no recurrence of infusion reactions. Although the benefit to risk ratio of Herceptin remains favorable, physicians must be vigilant and aggressive in managing cardiotoxicity and infusion-related reactions.
© 2001 S. Karger AG, Basel
Adams VR: Adverse events associated with chemotherapy for common cancers. Pharmacotherapy 2000;20:S96–S103.
Brenner TL, Adams VR: First MAb approved for the treatment of metastatic breast cancer. J Am Pharm Assoc 1999;39:236–238.
- Brockstein BE, Smiley C, Al-Sadir J, Williams SF: Cardiac and pulmonary toxicity in patients undergoing high dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000;25:885–894.
- Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of the anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285–4289.
- Cobleigh MA, Vogel CL, Tripothy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
- Dhingra K: Antiestrogens – tamoxifen, SERMS and beyond. Invest New Drugs 1999;17:285–311.
- Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving Trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artefact? Semin Oncol 1999;26:96–101.
- Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000;102:272–274.
- Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269–286.
- Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Ballaire BK: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26:66–73.
- Henderson IC, Garber JE, Breitmeyer JB, Hayes DF, Harris JR: Comprehensive management of disseminated breast cancer. Cancer 1990;66:1439–1448.
- Hoekman K, van der Vijgh WJ, Vermorken JB: Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 1999;57:133–155.
- Lefrak E, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathological analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302–314.
- Leget GA, Czuczman MS: Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548–551.
- Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT: Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Practice 1999;7:59–65.
Maloney DG, Press OW: Newer treatments for non-Hodgkin’s lymphoma: monoclonal antibodies. Oncology 1998;12:63–76.
Mass RD, Sanders C, Charlene K, Johnson L, Everett T, Anderson S: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000;19:75A.
Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:127A.
- Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.
- Robinson E, Kimmick GG, Musa HB: Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 1996;8:329–337.
- Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413–428.
- Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–905.
- Slamon DJ, Clark GM, Wong SG Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.
- Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S: First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 2000;19:71A.
- Weiner LM: An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999;26:41–50.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.